Other Clinical Trial - China STEMI Care Project

Status Recruiting

Clinical Trial Summary

The China ST-elevation myocardial infarction (STEMI) Care Project (CSCAP) aims to improve the reperfusion treatment rate and shorten the total duration of myocardial ischemia by establishing a regional STEMI treatment network covering the whole-city region, whole-city population, and whole-disease process step by step. The CSCAP is a prospective, multicenter registry involving three phases. A total of 18 provinces, 4 municipalities, and 2 autonomous regions in China were included. Patients with STEMI who met with the third acute myocardial infarction definition and the Chinese STEMI diagnosis and treatment guidelines were enrolled and the estimated number is over 50,000. Phase 1 (CSCAP-1) focused on the in-hospital process optimization of primary percutaneous coronary intervention (PPCI) hospitals. Phase 2 (CSCAP-2) focused on the PPCI hospital-based regional STEMI transfer network, including emergency medical services and non-PPCI hospitals. Phase 3 (CSCAP-3) focused on the whole-city STEMI care network construction by promoting chest pain center accreditation. Systematic data collection, assessment of quality of care, and subsequent improvement were implemented throughout the project to continuously improve the quality of care for patients with STEMI.

CSCAP is the first project that focused on establishing a regional STEMI emergency care network in China to help understand the condition of STEMI care in China extensively. Moreover, its objective was to optimize the quality of STEMI care through in-hospital process optimization (2012-2013), PPCI hospital-based regional STEMI transfer network construction (2015-2018), and construction of the whole-city STEMI care network step by step (2018-2021). However, hospitals were not randomly selected in CSCAP, which might be because of the lack of representatives to some degree. Alternatively, it focused on providing a tailored quality-of-care improvement plan based on the conditions of different regions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
ST-Elevation Myocardial Infarction

Clinical Trial Details

NCT number	NCT03821012
Study type	Observational
Source	Peking University First Hospital
Contact	Yan Zhang, MD
Phone	8610-83575728
Email	drzhy1108@163.com
Status	Recruiting
Phase
Start date	January 2011
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01864343` - Target Temperature Management In Myocardial Infarction - A Pilot Study	N/A
Completed	`NCT00962416` - Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI)	Phase 4
Active, not recruiting	`NCT00927615` - Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)	N/A
Completed	`NCT03135275` - MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial	N/A
Recruiting	`NCT02592694` - Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty	Phase 4
Withdrawn	`NCT01991366` - Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Completed	`NCT02158468` - Effect of Conditioning on Myocardial Damage in STEMI	N/A
Completed	`NCT01197729` - OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry	N/A
Completed	`NCT06426537` - Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches	Early Phase 1
Completed	`NCT01882179` - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size	Phase 3
Terminated	`NCT00719914` - A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks	Phase 2
Completed	`NCT00952224` - Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome	N/A
Completed	`NCT00378391` - European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry	N/A
Withdrawn	`NCT04303377` - Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction	Phase 2
Completed	`NCT03523624` - Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
Completed	`NCT01531114` - PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus	Phase 3
Active, not recruiting	`NCT01960933` - Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization	N/A
Completed	`NCT00502528` - Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction	Phase 2
Recruiting	`NCT02062554` - Brasilia Heart Study
Recruiting	`NCT04150016` - In-stent Repair and Vessel Reaction of STEMI Patients With OCT	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.